{"id":"peg-intron-ribavirin","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Flu-like symptoms"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Headache"},{"rate":"10-30%","effect":"Depression"},{"rate":"10-20%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL405705","moleculeType":"Small molecule","molecularWeight":"1256.27"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PEG-Intron works by binding to interferon receptors on the surface of cells, triggering a signaling cascade that activates immune cells and increases the production of antiviral proteins. Ribavirin, on the other hand, is a nucleoside analog that is incorporated into viral RNA, causing chain termination and preventing viral replication.","oneSentence":"PEG-Intron is a pegylated form of interferon-alpha, which is used to stimulate the body's immune response to fight viral infections, while Ribavirin is an antiviral medication that works by inhibiting viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:07.420Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"}]},"trialDetails":[{"nctId":"NCT01466192","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Chronic Hepatitis C","enrollment":108},{"nctId":"NCT00630058","phase":"PHASE1","title":"A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT00780910","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":"Chronic Hepatitis C","enrollment":109},{"nctId":"NCT00780416","phase":"PHASE3","title":"Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":"Hepatitis C","enrollment":189},{"nctId":"NCT00781274","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-12","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT01468584","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-11","conditions":"Chronic Hepatitis C","enrollment":10},{"nctId":"NCT01718301","phase":"PHASE3","title":"HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin","status":"TERMINATED","sponsor":"Anna Cruceta","startDate":"2013-03-10","conditions":"Hepatitis C, HIV Infections, COINFECTION","enrollment":108},{"nctId":"NCT01340573","phase":"","title":"Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-23","conditions":"Chronic Hepatitis C","enrollment":3},{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":368},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT01678131","phase":"PHASE1","title":"Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-30","conditions":"Chronic Hepatitis C","enrollment":31},{"nctId":"NCT04382937","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2016-01-12","conditions":"Chronic Hepatitis C Virus Infection","enrollment":222},{"nctId":"NCT01482767","phase":"PHASE3","title":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"HIV Infections, Hepatitis C","enrollment":262},{"nctId":"NCT00015652","phase":"NA","title":"Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":24},{"nctId":"NCT00381953","phase":"PHASE3","title":"High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2003-02","conditions":"Hepatitis C","enrollment":33},{"nctId":"NCT00910624","phase":"PHASE3","title":"Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-06-22","conditions":"Hepatitis C, Chronic","enrollment":168},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT01023035","phase":"PHASE3","title":"Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-07","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT01590225","phase":"PHASE3","title":"Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-28","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT01364090","phase":"PHASE4","title":"A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":93},{"nctId":"NCT00919633","phase":"PHASE2","title":"Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C","status":"COMPLETED","sponsor":"Medtronic Corporate Technologies and New Ventures","startDate":"2009-06","conditions":"Hepatitis C","enrollment":116},{"nctId":"NCT02247440","phase":"PHASE4","title":"HCV-HIV Co-infected Patient Cohort in Thailand","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2014-08","conditions":"Hepatitis C Infection, HIV","enrollment":18},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01606800","phase":"PHASE4","title":"Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-01","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT01405937","phase":"PHASE3","title":"Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-08-29","conditions":"Hepatitis C, Chronic","enrollment":51},{"nctId":"NCT01370642","phase":"PHASE3","title":"Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":294},{"nctId":"NCT01405560","phase":"PHASE3","title":"Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-02","conditions":"Hepatitis C, Chronic","enrollment":42},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT00689390","phase":"PHASE2, PHASE3","title":"Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-20","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":1954},{"nctId":"NCT01756079","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-06","conditions":"Hepatitis C","enrollment":58},{"nctId":"NCT02103439","phase":"PHASE3","title":"An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-06-06","conditions":"Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection","enrollment":140},{"nctId":"NCT01945294","phase":"PHASE3","title":"Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-10","conditions":"Hepatitis C, Chronic","enrollment":257},{"nctId":"NCT02060058","phase":"PHASE3","title":"Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2013-11","conditions":"Hepatitis C, Chronic","enrollment":12},{"nctId":"NCT00803309","phase":"PHASE4","title":"Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients","status":"TERMINATED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2008-11","conditions":"Hepatitis C, Chronic","enrollment":99},{"nctId":"NCT02099604","phase":"PHASE3","title":"Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-04","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00317746","phase":"PHASE3","title":"Trial of Citalopram for the Prevention of Depression","status":"COMPLETED","sponsor":"Marina Klein","startDate":"2006-11","conditions":"Depression, HIV Infections, Hepatitis C","enrollment":76},{"nctId":"NCT00493805","phase":"PHASE4","title":"Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hepatitis C, Chronic, Insulin Resistance","enrollment":59},{"nctId":"NCT00423800","phase":"PHASE3","title":"Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis C, Chronic","enrollment":56},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00686777","phase":"PHASE4","title":"Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":75},{"nctId":"NCT00863109","phase":"","title":"Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Hepatitis C, Chronic, Genotype 1, HCV-1","enrollment":133},{"nctId":"NCT00687219","phase":"PHASE3","title":"Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Hepatitis C, Chronic, Liver Cirrhosis","enrollment":102},{"nctId":"NCT00759109","phase":"PHASE3","title":"Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-03","conditions":"Carcinoma, Hepatocellular","enrollment":150},{"nctId":"NCT00705432","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":1472},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT00378599","phase":"PHASE3","title":"Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis","enrollment":125},{"nctId":"NCT00687544","phase":"PHASE4","title":"Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12","conditions":"Hepatitis C, Chronic, Hepacivirus, HIV Infections","enrollment":11},{"nctId":"NCT00255008","phase":"PHASE4","title":"Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00202839","phase":"PHASE4","title":"Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":160},{"nctId":"NCT00265395","phase":"PHASE3","title":"Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":1428},{"nctId":"NCT00686517","phase":"PHASE3","title":"Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-12","conditions":"Hepatitis C","enrollment":130},{"nctId":"NCT00302081","phase":"PHASE3","title":"Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08","conditions":"Hepatitis C, Chronic","enrollment":696},{"nctId":"NCT00441584","phase":"PHASE3","title":"The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Hepatitis C, Chronic","enrollment":117},{"nctId":"NCT00423670","phase":"PHASE2","title":"Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01","conditions":"Chronic Hepatitis C","enrollment":765},{"nctId":"NCT00104052","phase":"PHASE3","title":"Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT00048724","phase":"PHASE3","title":"Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":631},{"nctId":"NCT00081770","phase":"PHASE3","title":"Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-03","conditions":"Hepatitis C, Chronic","enrollment":4469},{"nctId":"NCT00049842","phase":"PHASE3","title":"Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-10","conditions":"Chronic Hepatitis C, Liver Fibrosis","enrollment":540},{"nctId":"NCT00039871","phase":"PHASE3","title":"PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-05","conditions":"Hepatitis, Hepatitis C, Chronic, Fibrosis","enrollment":2333},{"nctId":"NCT00761735","phase":"PHASE3","title":"5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Hepatitis C, Chronic","enrollment":94},{"nctId":"NCT01447446","phase":"","title":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":4442},{"nctId":"NCT00248339","phase":"PHASE3","title":"Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2002-05","conditions":"Hepatitis C","enrollment":150},{"nctId":"NCT01770223","phase":"PHASE4","title":"A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00811967","phase":"PHASE3","title":"Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-02","conditions":"Hepatitis C, Chronic, Liver Cirrhosis","enrollment":50},{"nctId":"NCT00277238","phase":"PHASE2","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02","conditions":"Hepatitis, Chronic Active","enrollment":113},{"nctId":"NCT00422838","phase":"","title":"Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2007-01","conditions":"Hepatitis C, Liver, Immunology","enrollment":20},{"nctId":"NCT01463956","phase":"PHASE2","title":"Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2012-01-06","conditions":"HCV Infection, Liver Cirrhosis, Experimental","enrollment":58},{"nctId":"NCT01280656","phase":"","title":"A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Hepatitis C, Chronic","enrollment":660},{"nctId":"NCT00759200","phase":"PHASE2","title":"Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Chronic Hepatitis C","enrollment":525},{"nctId":"NCT01838772","phase":"PHASE4","title":"HCV Treatment in HIV Co-Infected Patients in Asia","status":"COMPLETED","sponsor":"amfAR, The Foundation for AIDS Research","startDate":"2013-12","conditions":"Hepatitis C, HIV","enrollment":188},{"nctId":"NCT01066819","phase":"","title":"PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":1656},{"nctId":"NCT01701063","phase":"PHASE1, PHASE2","title":"An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-01","conditions":"Hepatitis C","enrollment":42},{"nctId":"NCT00087607","phase":"PHASE4","title":"Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Hepatitis C, Chronic","enrollment":385},{"nctId":"NCT00087568","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-01","conditions":"Hepatitis C, Chronic","enrollment":57},{"nctId":"NCT01066793","phase":"","title":"PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Hepatitis C, Chronic","enrollment":2343},{"nctId":"NCT02168361","phase":"PHASE4","title":"The SIM-SOF Trial for Hepatitis C","status":"COMPLETED","sponsor":"Center For Hepatitis C, Atlanta, GA","startDate":"2013-12","conditions":"Chronic Hepatitis C","enrollment":93},{"nctId":"NCT00087646","phase":"PHASE4","title":"REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-09","conditions":"Hepatitis C, Chronic","enrollment":948},{"nctId":"NCT00723645","phase":"","title":"Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-04","conditions":"Hepatitis C, Chronic","enrollment":279},{"nctId":"NCT00709059","phase":"","title":"Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":538},{"nctId":"NCT00723879","phase":"","title":"Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-10","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":115},{"nctId":"NCT00723892","phase":"","title":"Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":614},{"nctId":"NCT00724464","phase":"","title":"Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":332},{"nctId":"NCT01547312","phase":"PHASE1","title":"Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00160251","phase":"PHASE2","title":"Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Chronic Hepatitis C","enrollment":357},{"nctId":"NCT01016912","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis C Infection","enrollment":51},{"nctId":"NCT00727311","phase":"","title":"Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":2302},{"nctId":"NCT00726557","phase":"","title":"Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Hepatitis C, Chronic, Substance Abuse, Intravenous","enrollment":246},{"nctId":"NCT00725205","phase":"","title":"Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-03","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":294},{"nctId":"NCT00704964","phase":"","title":"Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-05","conditions":"Hepatitis C, Chronic Hepatitis C","enrollment":746},{"nctId":"NCT00704522","phase":"","title":"Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":601},{"nctId":"NCT00725751","phase":"","title":"Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Hepatitis C, Chronic","enrollment":353},{"nctId":"NCT00723632","phase":"","title":"Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":901},{"nctId":"NCT00705666","phase":"","title":"Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":789},{"nctId":"NCT00724373","phase":"","title":"Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11","conditions":"Hepatitis C, Chronic","enrollment":442}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Peginterferon alfa-2b"],"phase":"phase_3","status":"active","brandName":"PEG-Intron + Ribavirin","genericName":"PEG-Intron + Ribavirin","companyName":"PharmaEssentia","companyId":"pharmaessentia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEG-Intron is a pegylated form of interferon-alpha, which is used to stimulate the body's immune response to fight viral infections, while Ribavirin is an antiviral medication that works by inhibiting viral replication. Used for Chronic hepatitis C, Chronic hepatitis B.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}